| Item type |
文献 / Documents(1) |
| 公開日 |
2020-06-22 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1186/1471-2202-15-79 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1186/1471-2202-15-79 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease |
|
言語 |
en |
| 著者 |
カドグチ, ナオト
オカベ, シンジ
ヤマムラ, ユキオ
ショウノ, ミサキ
フカノ, タツヤ
タナベ, アキエ
ヨコヤマ, ヒロノリ
笠原, 二郎
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), shows multiple pharmacological actions such as inhibiting presynaptic α2 noradrenaline receptor (NAR) and selectively activating 5-hydroxytriptamine (5-HT) 1A receptor (5-HT1AR). Mirtazapine was also reported to increase dopamine release in the cortical neurons with 5-HT dependent manner. To examine whether mirtazapine has a therapeutic potency in Parkinson’s disease (PD), we examined this compound in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice model of PD.
Results: Male C57BL/6 mice were subjected to MPTP treatment to establish a PD model. Mirtazapine was administered once a day for 3 days after MPTP treatment. MPTP-induced motor dysfunction, assessed by beam-walking and rota-rod tests, was significantly improved by administration of mirtazapine. Biochemical examinations by high performance liquid chromatography and western blot analysis suggested mirtazapine facilitated utilization of dopamine by increasing turnover and protein expression of transporters, without affecting on neurodegenerative process by MPTP. These therapeutic effects of mirtazapine were reduced by administration of WAY100635, an inhibitor for 5HT1AR, or of clonidine, a selective agonist for α2-NAR, or of prazosin, an inhibitor for α1-NAR, respectively.
Conclusion: Our results showed mirtazapine had a therapeutic potency against PD in a mouse model. Because PD patients sometimes show depression together, it will be a useful drug for a future PD treatment. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Parkinson’s disease |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Mirtazapine |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Noradrenergic and specific serotonergic antidepressant (NaSSA) |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Serotonin (5-hydroxytryptamine, 5-HT) |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Dopamine |
| 書誌情報 |
en : BMC Neuroscience
巻 15,
p. 79,
発行日 2014-06-25
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
14712202 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12035336 |
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
BioMed Central |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
© 2014 Kadoguchi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| EID |
|
|
識別子 |
303232 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
bmcn_15_79.pdf (790 KB)
.png)
